Notice: Trying to get property of non-object in /srv/www/html/sustainabledevelopment.un.org/root/content.php on line 243
Merck commits an estimated $840 million over the next 5 years through their HIV prevention and treatment, childhood asthma programs and donation of HPV vaccine .:. Sustainable Development Knowledge Platform
Merck commits an estimated $840 million over the next 5 years through their HIV prevention and treatment, childhood asthma programs and donation of HPV vaccine
(Ratings from 0 users)
Rate this page/content 1-5
0 Comments
Information
  • Submitted by: Merck
  • Topic: Health and population
  • Keywords: Financial Mechanism; AIDS; Children and Women's Health; Youth; Population and Development
  • Location: Low-income Countries
  • Date of completion: 2015
  • Click for more information
Documents
Action Network
  • This voluntary initiative came from Every Woman Every Child
Deliverables
Deliverable Date
Merck commits an estimated $840 million over the next 5 years through their HIV prevention and treatment, childhood asthma programs and donation of HPV vaccine, GARDASIL®, to organizations and institutions in eligible lowest income countries to enable countries to develop capacity to implement vaccination programs. 2015
Resources devoted to implementation
Type Details
Financing (in USD) $840,000,000
In-kind contribution Increasing access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world through up to five million doses of GARDASIL and HPV DNA tests to screen an additional 500,000 women.
Description
Partner(s)
Qiagen
Description/achievement of initiative
2010: Merck commits an estimated $840 million over the next 5 years through their HIV prevention and treatment, childhood asthma programs and donation of HPV vaccine, GARDASIL®, to organizations and institutions in eligible lowest income countries to enable countries to develop capacity to implement vaccination programs. Merck and Qiagen are also committed to increasing access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world through up to five million doses of GARDASIL and HPV DNA tests to screen an additional 500,000 women. The two companies will also support the development and implementation of sustainable best practice models for cervical cancer reduction in low-income, high disease burden countries.
Implementation methodologies
Through Merck's HIV prevention and treatment, childhood asthma programs and donation of HPV vaccine, GARDASIL®, to organizations and institutions in eligible lowest income countries to enable countries to develop capacity to implement vaccination programs. Merck will also partner with Qiagen in increasing access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

Copyright United Nations Department of Economic and Social Affairs

Notice: Trying to get property of non-object in /srv/www/html/sustainabledevelopment.un.org/root/content.php on line 590